| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $391,004,524 | 14 | 100 |
| McHugh Julie | director | 0 | $0 | 1 | $423,771 | $-423,771 |
| Blanchfield Paul | President | 0 | $0 | 3 | $893,767 | $-893,767 |
| Niedzwiecki Daniel | See Remarks | 0 | $0 | 2 | $950,340 | $-950,340 |
| Heino Mary Anne | director | 0 | $0 | 2 | $2M | $-2M |
| Marshall Robert J. Jr. | CFO and Treasurer | 0 | $0 | 2 | $4.31M | $-4.31M |
| FARALLON PARTNERS L L C/CA | Member of a Group Owning 10% | 0 | $0 | 2 | $191.21M | $-191.21M |
| PATEL RAJIV A | Member of a Group Owning 10% | 0 | $0 | 2 | $191.21M | $-191.21M |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Over the last 12 months, insiders at Lantheus Holdings, Inc. have bought $0 and sold $391M worth of Lantheus Holdings, Inc. stock.
On average, over the past 5 years, insiders at Lantheus Holdings, Inc. have bought $0 and sold $91.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $18,600 was made by Maeusli Heinz Christoph (director) on 2021‑03‑05.
| 2025-08-20 | Sale | PATEL RAJIV A | Member of a Group Owning 10% | 3.37M 4.9498% | $56.15 | $188.94M | +4.47% | |
| 2025-08-20 | Sale | FARALLON PARTNERS L L C/CA | Member of a Group Owning 10% | 3.37M 4.9498% | $56.15 | $188.94M | +4.47% | |
| 2025-08-19 | Sale | PATEL RAJIV A | Member of a Group Owning 10% | 41,000 0.0605% | $55.34 | $2.27M | +6.17% | |
| 2025-08-19 | Sale | FARALLON PARTNERS L L C/CA | Member of a Group Owning 10% | 41,000 0.0605% | $55.34 | $2.27M | +6.17% | |
| 2025-08-13 | Sale | Blanchfield Paul | President | 3,060 0.0045% | $53.57 | $163,924 | +8.07% | |
| 2025-06-13 | Sale | Niedzwiecki Daniel | See Remarks | 6,000 0.0088% | $78.74 | $472,440 | -18.06% | |
| 2025-06-09 | Sale | Marshall Robert J. Jr. | CFO and Treasurer | 39,773 0.0573% | $83.00 | $3.3M | -22.47% | |
| 2025-06-09 | Sale | McHugh Julie | director | 5,192 0.0074% | $81.62 | $423,771 | -22.47% | |
| 2025-06-05 | Sale | Blanchfield Paul | President | 6,599 0.0095% | $79.65 | $525,610 | -19.41% | |
| 2025-06-05 | Sale | Niedzwiecki Daniel | See Remarks | 6,000 0.0086% | $79.65 | $477,900 | -19.41% | |
| 2025-06-02 | Sale | Heino Mary Anne | director | 26,066 0.0375% | $76.83 | $2M | -15.51% | |
| 2025-03-17 | Sale | Marshall Robert J. Jr. | CFO and Treasurer | 10,000 0.0143% | $100.52 | $1.01M | -34.50% | |
| 2025-03-13 | Sale | Heino Mary Anne | director | 2 <0.0001% | $100.13 | $200 | -32.11% | |
| 2025-03-05 | Sale | Blanchfield Paul | President | 2,084 0.003% | $98.00 | $204,232 | -32.54% | |
| 2025-03-03 | Sale | Heino Mary Anne | director | 53,107 0.0769% | $94.35 | $5.01M | -28.47% | |
| 2025-01-15 | Sale | Thrall James H | director | 1,000 0.0015% | $94.76 | $94,760 | -21.53% | |
| 2024-11-15 | Sale | Marshall Robert J. Jr. | CFO and Treasurer | 10,000 0.0143% | $81.20 | $812,000 | +5.09% | |
| 2024-11-14 | Sale | Blanchfield Paul | President | 2,000 0.0028% | $79.65 | $159,300 | -0.24% | |
| 2024-11-08 | Sale | Heino Mary Anne | director | 11,487 0.0167% | $87.16 | $1M | -7.61% | |
| 2024-08-21 | Sale | Thrall James H | director | 1,000 0.0014% | $98.52 | $98,520 | -9.57% |
| FARALLON PARTNERS L L C/CA | Member of a Group Owning 10% | 3477227 5.114% | $270.67M | 0 | 2 | |
| PATEL RAJIV A | Member of a Group Owning 10% | 3477227 5.114% | $270.67M | 0 | 2 | |
| Heino Mary Anne | director | 318650 0.4686% | $24.8M | 0 | 43 | |
| Blanchfield Paul | President | 108214 0.1592% | $8.42M | 0 | 19 | |
| Marshall Robert J. Jr. | CFO and Treasurer | 88860 0.1307% | $6.92M | 0 | 26 | |
| Niedzwiecki Daniel | See Remarks | 87057 0.128% | $6.78M | 0 | 14 | |
| McHugh Julie | director | 25962 0.0382% | $2.02M | 0 | 8 | |
| Venkataraman Sriram | 1846996 2.7164% | $143.77M | 0 | 2 | ||
| Crowley John W. | CFO | 138656 0.2039% | $10.79M | 0 | 2 | |
| Avista Capital Partners GP, LLC | 10 percent owner | 122492 0.1802% | $9.53M | 0 | 7 | |
| DUFFY MICHAEL P | SVP and General Counsel | 109472 0.161% | $8.52M | 0 | 24 | |
| Bolla John J. | Chief Operations Officer | 102440 0.1507% | $7.97M | 0 | 7 | |
| Orlandi Cesare | Chief Medical Officer | 68483 0.1007% | $5.33M | 0 | 13 | |
| Montagut Etienne | Chief Business Officer | 67254 0.0989% | $5.24M | 0 | 15 | |
| Walker Carol | Senior Vice President, Quality | 64899 0.0954% | $5.05M | 0 | 4 | |
| Healey Timothy G | SVP, Commercial | 60886 0.0895% | $4.74M | 0 | 3 | |
| Sabens Andrea | Chief Accounting Officer | 60420 0.0889% | $4.7M | 0 | 33 | |
| LENO SAM R | director | 57937 0.0852% | $4.51M | 0 | 9 | |
| Robertson A Frederick | director | 40402 0.0594% | $3.14M | 0 | 2 | |
| Burgstahler David F | director | 38269 0.0563% | $2.98M | 0 | 17 | |
| Thrall James H | director | 33207 0.0488% | $2.58M | 0 | 3 | |
| Molnar Istvan | Chief Medical Officer | 25130 0.037% | $1.96M | 0 | 1 | |
| Maeusli Heinz Christoph | director | 23340 0.0343% | $1.82M | 8 | 1 | +41.74% |
| Ber Gerard | director | 21221 0.0312% | $1.65M | 0 | 2 | |
| MARKISON BRIAN A | 19318 0.0284% | $1.5M | 0 | 17 | ||
| SCHAFFER DERACE L | director | 16994 0.025% | $1.32M | 0 | 9 | |
| Pruden Gary J | director | 11978 0.0176% | $932,367.52 | 0 | 2 | |
| Baylor-Henry Minnie | director | 16 0% | $1,245.44 | 0 | 1 |
$910,099,463 | 123 | 11.52% | $2.08B | |
$25,130,034 | 62 | -7.01% | $12.13B | |
$14,599,168 | 59 | 12.79% | $1.72B | |
$102,709,455 | 46 | 30.55% | $983.47M | |
$11,542,910 | 40 | 56.19% | $1.45B | |
$21,020,549 | 38 | -2.84% | $13.39B | |
$73,312,053 | 38 | -4.37% | $1.61B | |
$12,998,723 | 30 | 3.46% | $4.18B | |
$6,506,230 | 27 | -16.20% | $1B | |
$78,335,024 | 20 | 4.76% | $55.52B | |
$25,034,841 | 20 | 9.38% | $608.42M | |
$83,406,412 | 19 | 21.96% | $3.19B | |
$2,233,486 | 16 | -3.34% | $16.94B | |
$1,843,996 | 10 | 22.92% | $917.21M | |
$26,633,903 | 9 | 42.23% | $1.25B | |
$1,718,514 | 9 | 38.13% | $739.11M | |
Lantheus Holdings, Inc. (LNTH) | $141,200 | 8 | 41.74% | $5.29B |
$614,633 | 6 | 27.86% | $2.1B | |
$32,954,224 | 5 | -0.22% | $37.73B |
| Increased Positions | 186 | +32.69% | 11M | +14.7% |
| Decreased Positions | 257 | -45.17% | 13M | -17.92% |
| New Positions | 70 | New | 4M | New |
| Sold Out Positions | 100 | Sold Out | 3M | Sold Out |
| Total Postitions | 498 | -12.48% | 69M | -3.23% |
| Blackrock, Inc. | $556,037.00 | 12.52% | 8.27M | -267,690 | -3.14% | 2025-09-30 |
| Vanguard Group Inc | $467,689.00 | 10.53% | 6.95M | +115,338 | +1.69% | 2025-09-30 |
| Janus Henderson Group Plc | $449,682.00 | 10.13% | 6.68M | -254,247 | -3.66% | 2025-09-30 |
| Fmr Llc | $282,465.00 | 6.36% | 4.2M | -820,140 | -16.34% | 2025-09-30 |
| Morgan Stanley | $260,883.00 | 5.88% | 3.88M | +3M | +423.5% | 2025-09-30 |
| Farallon Capital Management Llc | $233,913.00 | 5.27% | 3.48M | -3M | -48.27% | 2025-09-30 |
| State Street Corp | $167,975.00 | 3.78% | 2.5M | -61,593 | -2.41% | 2025-09-30 |
| Geode Capital Management, Llc | $118,025.00 | 2.66% | 1.75M | -22,431 | -1.26% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $92,233.00 | 2.08% | 1.37M | -12,042 | -0.87% | 2025-09-30 |
| Reinhart Partners, Llc. | $90,664.00 | 2.04% | 1.35M | -55,903 | -3.98% | 2025-09-30 |